Novartis says drug candidate is successful in rare kidney disease trial

Explore stories from Atlantic Canada.

Spice Up Your Life with Homemade Pumpkin Spice: No Bake Pie | SaltWire #shortsvideo #cookingshortsFRANKFURT - Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug trial.

Treatment with the drug candidate, acquired as part of the purchase of U.S. biotech firm Chinook Therapeutics for up to $3.5 billion, resulted in a clinically meaningful improvement in kidney filtration in patients suffering from IgA nephropathy when compared to placebo, the Swiss drugmaker said in a statement.

Novartis added it plans to review the interim results with the U.S. Food and Drug Administration with a view to a regulatory filing for accelerated approval.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

SaltWire Network /  🏆 45. in CA

Philippines Latest News, Philippines Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Read more »

Twelve dead after plane crashes in Brazil's Acre stateExplore stories from Atlantic Canada.
Read more »

Data scarce on what green energy transition will cost Nova ScotiansExplore stories from Atlantic Canada.
Read more »